Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Head-and-neck
100%
Concurrent Radiotherapy
100%
Locally Advanced
100%
Concurrent Cisplatin
100%
Metformin
100%
Squamous Cell Cancer
100%
Dose Finding
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
44%
Chemoradiotherapy
33%
Overall Survival
22%
Cisplatin
22%
Progression-free Survival
22%
Acute Kidney Injury
22%
Patient Demographics
11%
Number of Patients
11%
Adverse Events
11%
Radiotherapy
11%
Anemia
11%
5-year Survival
11%
Vomiting
11%
Diarrhea
11%
Dose-limiting Toxicity
11%
Escalating Dose
11%
Maximum Tolerated Dose
11%
Non-diabetic
11%
Phase II Trial
11%
Leukopenia
11%
Phase 1 Trial
11%
Nausea
11%
Overall Survival Rate
11%
Hypoglycemia
11%
Lactic Acidosis
11%
Dose-escalation Study
11%
Antidiabetic Agents
11%
Tobacco Users
11%
Mucositis
11%
Divided Dose
11%
National Cancer Institute Common Terminology Criteria for Adverse Events
11%
P16-positive
11%
Medicine and Dentistry
Neck
100%
Cancer Cell
100%
Cisplatin
100%
Squamous Cell
100%
Glycon
100%
Radiation Therapy
100%
Overall Survival
30%
Chemoradiotherapy
30%
Head and Neck Squamous Cell Carcinoma
30%
Adverse Event
20%
Survival Rate
20%
Progression Free Survival
20%
Acute Kidney Injury
20%
Malignant Neoplasm
10%
Pharmacokinetics
10%
Patient Population
10%
Diarrhea
10%
Anemia
10%
Retrospective Study
10%
Leukopenia
10%
Hypoglycemia
10%
P16
10%
Antidiabetic Agent
10%
Lactic Acidosis
10%
Nausea
10%
Diseases
10%
Mucositis
10%
Pharmacology, Toxicology and Pharmaceutical Science
Squamous Cell Carcinoma
100%
Cisplatin
100%
Metformin
100%
Overall Survival
30%
Chemoradiation Therapy
30%
Head and Neck Squamous Cell Carcinoma
30%
Adverse Event
20%
Survival Rate
20%
Progression Free Survival
20%
Acute Kidney Failure
20%
Malignant Neoplasm
10%
Maximum Tolerated Dose
10%
Retrospective Study
10%
Anemia
10%
Nausea
10%
Lactic Acidosis
10%
Antidiabetic Agent
10%
Hypoglycemia
10%
Diarrhea
10%
Leukopenia
10%
Mucosa Inflammation
10%
Pharmacokinetics
10%
Diseases
10%